Hans Hux starts planned retirement from B Braun Medical

Hans Hux
David Oates, left, and Hand Hux

Hans Hux is stepping from his role as Chairman and Group Chief Executive of B Braun Medical into a non-executive Group Chairman role as part of a planned retirement process.

On his’ retirement, David Oates, former MD for sales and marketing at B. Braun, will become the firm’s UK Group Managing Director from Monday 1, July.

Hans will remain in the non-executive role until the end of January 2020 and will retire after more than 40 years – 27 of which saw him as head of the company’s UK operations.

One of the sector’s longest serving company heads, Hans moved to Sheffield in 1993 following eight years setting up Aesculap B. Braun in Japan. Initially Managing Director of Aesculap, when the company merged with B. Braun Medical Ltd, Hans became Chairman and Group Chief Executive of the expanded organisation.

Hans said: “To have the chance as a relatively young man to become Managing Director, to come to Sheffield with the task of re-engineering an organisation that was going nowhere and then to amalgamate two companies to launch B. Braun Medical was just extraordinary.

“In 1993 we more or less relied on very few products but through an evolutionary process of innovation and diversification we have substantially increased the breadth and range of our product portfolio and developed new businesses and services which have really enabled us to establish B. Braun in the UK as a leading healthcare provider.”

Based at Thorncliffe Park, the company operates in 18 therapy areas and during Hans’ leadership has developed a range of innovative technologies and services including safe infusion technology, homecare patient services, high-end endoscopy, 3D visualisation for surgeons, computer navigated implantology in Orthopaedics and home haemodialysis services.

Hans is Life Vice President of the Sheffield Sharks, as well as a former Sheffield Chamber of Commerce president and was inducted into the Chamber’s Hall of Fame in 2018 for his ‘exemplary dedication to staff welfare, research and development and ongoing investment’. In the same year he was elected a ‘Guardian’ by Sheffield Assay Office thanks to his ‘unrivalled industry expertise’.

Over his years at the helm, Hans has seen B. Braun Medical Ltd awarded the coveted Investors in People (IiP) Gold status three consecutive times, while Aesculap Academia UK, the educational arm of the business, was awarded a prestigious quality mark by the Royal College of Surgeons of England.

New MD David Oates joined the company in 2001 and during his time at the firm has been regional head of sales for the company’s Hospital Care Division which included Belgium, Ireland, Netherlands and the UK, and also the Director of the Hospital Care Division UK.

He said: “It is an exciting time but also very challenging. Healthcare is a very competitive market and we have to work very hard on prices, and make sure our products, services and support are of the highest possible quality.

“I would like us to be seen as one of the leading four or five health technology companies operating in the UK who are clearly seen as partners to the NHS and who are actively engaged in ensuring that British patients are getting access to the best possible care and treatment.

“To be able to have this opportunity is absolutely fantastic. It is a wonderful chance to continue the work that Hans has done in the UK while at the same time helping the organisation to evolve and develop and meet the challenges of today and tomorrow.”